6-fluoro-1-methylspiro[benzo[d][1,3]oxazine-4,4'-piperidin]-2(1H)-one | 1036926-64-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶嗪类
• 英文名称: 6-fluoro-1-methylspiro[benzo[d][1,3]oxazine-4,4'-piperidin]-2(1H)-one
• 英文别名: 6-fluoro-1-methylspiro[3,1-benzoxazine-4,4'-piperidine]-2-one
• CAS: 1036926-64-3
• 化学式: C₁₃H₁₅FN₂O₂
• 分子量: 250.273
• InChiKey: SUDIYJAVIKPUAF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  18
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-fluoro-1-methylspiro[benzo[d][1,3]oxazine-4,4'-piperidin]-2(1H)-one 在 四丁基氟化铵 作用下， 以 四氢呋喃 、 1,2-二氯乙烷 为溶剂， 反应 40.0h， 生成 2-((S)-2-((R)-2-(3,4-dichlorophenyl)-4-(6-fluoro-1-methyl-2-oxo-1,2-dihydrospiro[benzo[d][1,3]oxazine-4,4'-piperidine]-1'-yl)-2-methyl butanamido)-3-phenylpropanamido)ethyl carbamic acid benzyl ester
  参考文献：
  名称：

  Design, Synthesis, and Optimization of Balanced Dual NK₁/NK₃Receptor Antagonists

  摘要：

  In connection with a program directed at potent and balanced dual NK1/NK3 receptor ligands, a focused exploration of an original class of peptidomimetic derivatives was performed. The rational design and molecular hybridization of a novel phenylalanine core series was achieved to maximize the in vitro affinity and antagonism at both human NK1 and NK3 receptors. This study led to the identification of a new potent dual NK1/NK3 antagonist with pK(i) values of 8.6 and 8.1, respectively.

  DOI：

  10.1021/ml400528y
• 作为产物：
  描述：

  4-氟苯基氨基甲酸叔丁酯 在 叔丁基锂 、 caesium carbonate 、 三氟乙酸 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 正戊烷 为溶剂， 反应 49.92h， 生成 6-fluoro-1-methylspiro[benzo[d][1,3]oxazine-4,4'-piperidin]-2(1H)-one
  参考文献：
  名称：

  Design, Synthesis, and Optimization of Balanced Dual NK₁/NK₃Receptor Antagonists

  摘要：

  In connection with a program directed at potent and balanced dual NK1/NK3 receptor ligands, a focused exploration of an original class of peptidomimetic derivatives was performed. The rational design and molecular hybridization of a novel phenylalanine core series was achieved to maximize the in vitro affinity and antagonism at both human NK1 and NK3 receptors. This study led to the identification of a new potent dual NK1/NK3 antagonist with pK(i) values of 8.6 and 8.1, respectively.

  DOI：

  10.1021/ml400528y

文献信息

• Heterocyclic antiviral compounds
  申请人：Gabriel Stephen Deems

  公开号：US20080139544A1

  公开（公告）日：2008-06-12

  This invention relates to piperidine derivatives of formulae Ia and Ib with substituents as defined herein useful in the treatment of a variety of disorders, including those in which the modulation of CCR5 receptors is implicated. More particularly, the present invention relates to 1-oxa-3,8-diaza-spiro[4.5]decan-2-one and 1-oxa-3,9-diaza-spiro[5.5]undecan-2-one compounds and related derivatives, to compositions containing and to uses of such derivatives. Disorders that may be treated or prevented by the present derivatives include HIV and genetically related retroviral infections (and the resulting acquired immune deficiency syndrome, AIDS), diseases of the immune system and inflammatory diseases.

  本发明涉及式Ia和Ib的哌啶衍生物，其中所定义的取代基在治疗多种疾病中有用，包括涉及CCR5受体调节的疾病。更具体地说，本发明涉及1-氧杂-3,8-二氮杂螺[4.5]癸烷-2-酮和1-氧杂-3,9-二氮杂螺[5.5]十一烷-2-酮化合物及其相关衍生物，包括含有这些衍生物的组合物和这些衍生物的用途。本衍生物可用于治疗或预防的疾病包括艾滋病毒和遗传相关的逆转录病毒感染（及其导致的获得性免疫缺陷综合症，艾滋病），免疫系统疾病和炎症性疾病。
• SPIROPIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS
  申请人：Caroon Joanie Marie

  公开号：US20080176839A1

  公开（公告）日：2008-07-24

  The present invention relates to a compound of formula I wherein R 1 , R 2 , R 3 , R 4 , R 7 , m and n are as defined herein. These compounds are high potential NK-3 receptor antagonists useful for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).

  本发明涉及化合物I式，其中R1、R2、R3、R4、R7、m和n的定义如本文所述。这些化合物是高潜力NK-3受体拮抗剂，可用于治疗抑郁症、疼痛、精神病、帕金森病、精神分裂症、焦虑症和注意力缺陷多动障碍（ADHD）。
• US7332500B2
  申请人：——

  公开号：US7332500B2

  公开（公告）日：2008-02-19
• US7470684B2
  申请人：——

  公开号：US7470684B2

  公开（公告）日：2008-12-30
• US7538122B2
  申请人：——

  公开号：US7538122B2

  公开（公告）日：2009-05-26